Semaglutide is supplied as a modified glp-1 analogue for qualified laboratory research. It is intended for a modified glucagon-like peptide-1 analogue used in laboratory studies of GLP-1 receptor signalling, incretin biology, receptor binding and peptide analytical methods. Available specifications: 2 mg, 5 mg, 7 mg, 10 mg, 12 mg, 15 mg, 17 mg, 20 mg, 22 mg, 25 mg, 30 mg; 10 vials per box. For laboratory research use only. Not for human consumption, clinical use, diagnosis, treatment, compounding or veterinary use.